Octagon Capital
Overview
A multi-stage investment manager founded in 2019 that is dedicated to evidence-based investing in public and private healthcare companies, with a focus on the United States and China. The firm strives to build concentrated, long-term investments and partners with its portfolio companies. It manages capital for global institutions such as university endowments, non-profit foundations, family offices, and pension funds.
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Palisade Bio | Oct 2025 | Follow-on Offering | Co-investor |
| Aktis Oncology | Sep 2024 | Series B | Co-investor |
| Bluejay Therapeutics | May 2024 | Series C | Co-investor |
| Profound Bio | Feb 2024 | Series B | Co-investor |
| Tenaya Therapeutics | Feb 2024 | Follow-on Offering | Co-investor |
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
